Pharmacological Differentiation of Thrombomodulin Alfa and Activated Protein C on Coagulation and Fibrinolysis In Vitro

Clinical and Applied Thrombosis/Hemostasis

Volumn 24, Issue 6, 2018, Pages 859-866

  Tanaka, Kosuke ^a   Tawara, Shunsuke ^a   Tsuruta, Kazuhisa ^a   Hoppensteadt, Debra ^b   Fareed, Jawed ^b  

^a ASAHI KASEI PHARMA CORPORATION   (Japan)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

activated protein C; coagulation; fibrinolysis; thrombomodulin; thrombosis

Indexed keywords

ACTIVATED PROTEIN C; EDETIC ACID; INDOMETACIN; PLASMINOGEN ACTIVATOR; PROTHROMBIN; RECOMBINANT THROMBOMODULIN; THROMBIN; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID; PROTEIN C; RECOMBINANT PROTEIN; THBD PROTEIN, HUMAN;

ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; BLOOD CLOTTING TIME; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; HEMATOLOGY; HUMAN; PARTIAL THROMBOPLASTIN TIME; PHARMACOLOGY; PLASMA; PRIORITY JOURNAL; THROMBIN TIME; THROMBOELASTOGRAPHY; TURBIDITY; CELL LINE; DRUG EFFECT;

CELL LINE; FIBRINOLYSIS; HUMANS; PARTIAL THROMBOPLASTIN TIME; PROTEIN C; RECOMBINANT PROTEINS; THROMBOMODULIN; WHOLE BLOOD COAGULATION TIME;

EID: 85046773014     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029618770274     Document Type: Article

References (28)

1. Singer M, Deutschman CS, Seymour CW. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–810
2. Levi M, van der Poll T. Coagulation and sepsis. Thromb Res. 2017;149:38–44
3. Levi M, Poll T. Coagulation in patients with severe sepsis. Semin Thromb Hemost. 2015;41(1):9–15
4. de Pont AC, Bakhtiari K, Hutten BA. Recombinant human activated protein C resets thrombin generation in patients with severe sepsis—a case control study. Crit Care. 2005;9(5):R490–R497
5. Bernard GR, Vincent JL, Laterre PF. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699–709
6. Levi M. Activated protein C in sepsis: a critical review. Curr Opin Hematol. 2008;15(5):481–486
7. Ranieri VM, Thompson BT, Barie PS. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366(22):2055–2064
8. Thachil J, Toh CH, Levi M, Watson HG. The withdrawal of Activated Protein C from the use in patients with severe sepsis and DIC [Amendment to the BCSH guideline on disseminated intravascular coagulation]. Br J Haematol. 2012;157(4):493–494
9. Mohri M. ART-123: recombinant human soluble thrombomodulin. Cardiovasc Drug Rev. 2000;18(4):312–325
10. Mohri M, Sugimoto E, Sata M, Asano T. The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation–a comparison with other anticoagulants. Thromb Haemost. 1999;82(6):1687–1693
11. Tawara S, Sakai T, Matsuzaki O. Anti-inflammatory and anti-fibrinolytic effects of thrombomodulin alfa through carboxypeptidase B2 in the presence of thrombin. Thromb Res. 2016;147:72–79
12. Aikawa N, Shimazaki S, Yamamoto Y. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock. 2011;35(4):349–354
13. Saito H, Maruyama I, Shimazaki S. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5(1):31–41
14. Vincent JL, Ramesh MK, Ernest D. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med. 2013;41(9):2069–2079
15. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood. 1996;88(6):2093–2100
16. Lisman T, de Groot PG, Meijers JC, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood. 2005;105(3):1102–1105
17. Moore HB, Moore EE, Chapman MP. Viscoelastic measurements of platelet function, not fibrinogen function, predicts sensitivity to tissue-type plasminogen activator in trauma patients. J Thromb Haemost. 2015;13(10):1878–1887
18. Hemker HC, Giesen P, AlDieri R. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb. 2002;32(5-6):249–253
19. Nakamura K, Toyohira H, Kariyazono H, Yamada K, Moriyama Y, Taira A. Relationship between changes in F1+2 and TAT levels and blood coagulation early after prosthetic valve replacement. Thromb Res. 1997;86(2):161–171
20. Ganetsky M, Babu KM, Salhanick SD, Brown RS, Boyer EW. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol. 2011;7(4):281–287
21. Owada S, Tomita H, Kinjo T. CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough. Thromb Res. 2015;135(1):62–67
22. Kim SY, Gu JY, Yoo HJ. Benefits of thromboelastography and thrombin generation assay for bleeding prediction in patients with thrombocytopenia or hematologic malignancies. Ann Lab Med. 2017;37(6):484–493
23. Colucci M, Semeraro N. Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation. Thromb Res. 2012;129(3):314–319
24. Asakura H, Sano Y, Yamazaki M, Morishita E, Miyamoto K, Nakao S. Role of fibrinolysis in tissue-factor-induced disseminated intravascular coagulation in rats—an effect of tranexamic acid. Haematologica. 2004;89(6):757–758
25. Nagato M, Okamoto K, Abe Y, Higure A, Yamaguchi K. Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia. Crit Care Med. 2009;37(7):2181–2186
26. Osada K, Minami T, Arioka T. Thrombomodulin alfa attenuates the procoagulant effect and cytotoxicity of extracellular histones through the promotion of protein C activation. Thromb Res. 2017;160:51–57
27. Nakashima M, Kanamaru M, Umemura K, Tsuruta K. Pharmacokinetics and safety of a novel recombinant soluble human thrombomodulin, ART-123, in healthy male volunteers. J Clin Pharmacol. 1998;38(1):40–44
28. Moll S, Lindley C, Pescatore S. Phase I study of a novel recombinant human soluble thrombomodulin, ART-123. J Thromb Haemost. 2004;2(10):1745–1751